Would I use DCCT in clinic? My take on which patients it suits, from the Hormone Insight Podcast.
AI narration.
1
The harms and limits to weigh before you use DCCT, from the Hormone Insight Podcast.
AI narration.
3
In patients with type 1 diabetes, intensive insulin therapy markedly reduced the development and progression of retinopathy, nephropathy, and neuropathy compared with conventional therapy.
AI narration.
1
Would I use UKPDS in clinic? My take on which patients it suits, from the Hormone Insight Podcast.
AI narration.
3
In overweight patients with newly diagnosed type 2 diabetes, intensive glucose control with metformin reduced diabetes-related endpoints and all-cause mortality compared with conventional (mainly diet) therapy.
AI narration.
6
The harms and limits to weigh before you use UKPDS, from the Hormone Insight Podcast.
AI narration.
3
In newly diagnosed type 2 diabetes, intensive glucose control with a sulfonylurea or insulin reduced microvascular complications, but not macrovascular disease, compared with conventional diet therapy.
AI narration.
11
DIATEC: median inpatient time in range was 77.6% versus 62.7%. CGM was part of diabetes-team-guided insulin titration, not a standalone sensor intervention.
Read the PICO on Hormone Insight.
11
IoN supports omitting radioiodine in appropriately selected low-risk thyroid cancer. Non-inferiority is not a blanket recommendation for every patient after thyroidectomy.
Read the PICO on Hormone Insight.
7
Infrequent zoledronate: 10-year radiographic vertebral fracture rates were 6.3% versus 11.1% with placebo. Selected early postmenopausal women, not a universal dosing rule.
Read the PICO on Hormone Insight.
5
Baxdrostat and resistant hypertension. Explore the study design, endpoints and limitations.
Read the PICO on Hormone Insight.
15
OASIS-3: elinzanetant reduced vasomotor symptoms at week 12. Treatment-related adverse events were more common than with placebo. Benefit and tolerability belong in the same discussion.
Read the PICO on Hormone Insight.
8
TANDEM: obicetrapib plus ezetimibe lowered LDL at 84 days. The trial measured lipid efficacy, not cardiovascular event prevention. Read the result and its limits.
Read the PICO on Hormone Insight.
68
foresiGHt: weekly lonapegsomatropin improved trunk fat versus placebo in adult GH deficiency. A body-composition result, not proof of cardiovascular benefit or superiority to daily GH.
Read the PICO on Hormone Insight.
8
ORBIT: secukinumab did not demonstrate efficacy in Graves orbitopathy. Primary response at week 16: 0/14 versus 0/14 with placebo. Small trial; no basis for routine use.
Read the PICO on Hormone Insight.
11
Denosumab and teriparatide: a bone-biopsy study. Explore the study design, endpoints and limitations.
Read the PICO on Hormone Insight.
7
Prednisolone versus hydrocortisone: lower bone-turnover markers are not proof of fewer fractures. A small crossover trial, with important limits.
Read the PICO on Hormone Insight.
7











